ArticleBMC cancer2021
Risk and prognostic factors of breast cancer with liver metastases.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- A systematic literature review of prognostic factors in patients with HR+/HER2- advanced breast cancer in Japan.Japanese journal of clinical oncology · 2021Pooled it
- Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis.Cancer letters · 2026Review
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Breast Cancer Liver Metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.Research square · 2026Article
- Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors-A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.Palliative & supportive care · 2026Article
- Individualized prediction of survival after brain metastasis development in patients with breast cancer.Journal of neuro-oncology · 2026Article
- Efficacy and Safety of Selective Internal Radiation Therapy (SIRT) for Liver Metastases in Breast Cancer: An Umbrella Review.Cancers · 2026Review
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer.Cell death discovery · 2026Article
- Breast cancer liver metastases and the impact of receptor expression on survival.Clinical & experimental metastasis · 2026Article
- Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis.The breast journal · 2026Article
- Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.International medical case reports journal · 2026Article
- Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.Frontiers in oncology · 2026Article
- Yttrium-90 for the treatment of breast cancer liver metastases: a global propensity-matched study.Proceedings (Baylor University. Medical Center) · 2026Article
- Real-time survival assessment in breast cancer with liver metastasis.Discover oncology · 2025Article
- Heterogeneous tissue-specific macrophages orchestrate metastatic organotropism of breast cancer: implications for promising therapeutics.Journal of translational medicine · 2025Review
- Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.Clinical breast cancer · 2025Article
- Realizing the potential of nanomedicines to treat breast cancer liver metastasis.Nanomedicine (London, England) · 2025Article
- Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India.Ecancermedicalscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM).
methodsData on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients.
resultsYoung age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88-3.66; P < 0.001) and HR-/HER2+ (HR = 3.43; 95% CI = 2.28-5.15; P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74; 95% CI = 0.58-0.95; P < 0.001).
conclusionsBreast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.